🔎 Trials Near Me

Home › Atherosclerosis › NCT05867381

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History

Recruiting

Slowing Atherothrombosis Progression Through Indoor Air Filtration: A Crossover Trial in Hispanic and Non-Hispanic Adults With Ischemic Heart Disease History

Who can join

Ages 65 to 84 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Age between 65 and 84 years old;
* Weight ≥ 110 pounds;
* Nonsmokers for at least 1 year;
* Have ischemic heart disease history, clinically stable for 6 months, without any deterioration in symptoms or episodes of angina based on past electronic medical records;
* Both English and Spanish speaking participants will be included in the recruitment;
* Live in the Los Angeles County.

Exclusion Criteria:

* Have history of degenerative disease of the nervous system such as dementia and Alzheimer's;
* Currently have active cancer treatments;
* The residential house has already had HEPA filters;
* Participants will move out from the current residential address in the next 2 years;
* Participants will spend more than 1 month living outside the primary home;
* Have any health conditions that prohibit collecting health and covariate data and biospecimens;
* Participants' residential houses are not feasible for setting up air purifiers and air pollutants monitors.

About the study

This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.

What is being tested

Sponsor: University of Southern California · Participants: 112 · Started: Jul 11, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT05867381

Locations in the U.S.

CaliforniaKeck School of Medicine, University of Southern California, Los Angeles

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.